ClinicalTrials.gg
CompletedNCT04634812Updated Dec 16, 2025

Mass Balance Study of KBP-5074 in Healthy Male Subjects

A Phase 1 interventional study of KBP-5074 in Healthy, sponsored by KBP Biosciences. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by KBP Biosciences · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1, open-label, nonrandomized, single-dose mass balance and metabolite identification study in healthy male subjects.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Male Subjects
  • KBP-5074
03

In context

Lead sponsor

KBP Biosciences is the lead sponsor of 12 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males, of any race, between 18 and 55 years of age, inclusive, at screening.
  2. between 18.0 and 32.0 kg/m2, inclusive, at screening.
  3. In good health, determined by no findings from medical history, physical examination (assessed only at check-in), 12-lead , vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in as assessed by the investigator (or designee).
  4. History of a minimum of 1 bowel movement per day.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, psychiatric, or other disorder, as determined by the investigator (or designee).
  2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed; cholecystectomy will not be allowed).
  3. Positive urine drug screen, including cotinine, at screening; positive alcohol test result or positive urine drug screen, including cotinine, at check-in.
  4. Use of any drugs or substances known to be strong or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 or P-glycoprotein substrates within 30 days prior to study drug administration. Medications will be reviewed by the medical monitor to determine acceptability for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    [14C]-KBP-5074

    Drug: KBP-5074

Interventions

  • a single oral dose of \[14C\]-KBP-5074

06

What researchers measure

Primary outcomes

  1. Mass Balance of KBP-5074

    Percentage of total radioactivity recovered in urine and feces following a single dose \[14C\]-KBP-5074

    Time frame: up to 240 hours postdose

  2. Pharmacokinetic Parameter: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)

    Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma

    Time frame: up to 216 hours postdose

  3. Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)

    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma

    Time frame: up to 216 hours postdose

  4. Pharmacokinetic Parameter: Time of the maximum observed concentration (Cmax)

    Time of the maximum observed concentration (Cmax) - Plasma

    Time frame: up to 216 hours postdose

Secondary outcomes

  1. Metabolite radioprofiling and identification in plasma, urine and feces

    Select plasma, urine, and fecal samples will be processed and subject to metabolite analysis by LC/MS \& LC/MS/MS using high-resolution mass spectrometry.

    Time frame: up to 240 hours postdose

07

Study locations

1 site
  • Covance Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Dec 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2020
First posted
Nov 18, 2020
StartActual
Dec 3, 2020
Primary completionActual
Dec 23, 2020
CompletionActual
Dec 23, 2020
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04634812
Lead sponsor
KBP Biosciences
Collaborators
Covance
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Dec 3, 2020
Primary completion
Dec 23, 2020
Completion
Dec 23, 2020
Last update
Dec 16, 2025

Study contacts

James McCabe
study director · KBP Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KBP-5074

Start the discussion